Til hovedinnhold
Norli Bokhandel

Cannabinoids and Neuropsychiatric Disorders

2021, Heftet, Engelsk

1 699,-

Bestillingsvare – sendes normalt innen 10-14 virkedager
  • Gratis frakt på ordre fra 299,-
  • Bytt i 200 butikker
  • Ikke tilgjengelig for hent i butikk
This volume highlights the recent advances in the understanding of the endocannabinoid system and the likely benefit from the therapeutic effects of cannabinoid treatment in a variety of health issues. Archeological evidence has shown that Cannabis has a long history of use for multiple purposes, including the treatment of medical conditions. The primary active constituent of the hemp plant Cannabis sativa, delta 9-tetrahydrocannabinol (?9-THC), causes euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concentration and impairment of memory, among other effects. Despite these undesirable effects, signaling is mostly inhibitory and suggests a putative role for cannabinoids as therapeutic agents by managing several diseases where inhibition of neurotransmitter release would be beneficial. The themes of this book have been edited and  written by world-leaders in the field, The contents of the volume aims at readers from a range of academic and professional disciplines, such as biomedicine, several areas of biology, neurology, clinical medicine and pharmacy.

Produktegenskaper

  • Bidragsyter

    Eric Murillo-Rodriguez (Redaktør)
  • Forlag/utgiver

    Springer Nature Switzerland AG
  • Format

    Heftet
  • Språk

    Engelsk
  • Utgivelsesår

    2021
  • Antall sider

    153
  • Serienavn

    Advances in Experimental Medicine and Biology
  • EAN

    9783030573713

Kundeanmeldelser

Frakt og levering